The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and
South Africa 1 , 2 – 3 . It has since spread to many countries and is expected to rapidly become …

We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …

The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been
supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 …

Group A rotavirus classification is currently based on the molecular properties of the two outer
layer proteins, VP7 and VP4, and the middle layer protein, VP6. As reassortment of all the …

We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of
the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a …

Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the
emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

Background Ebola virus disease (EVD) is a highly lethal condition for which no specific
treatment has proven efficacy. In September 2014, while the Ebola outbreak was at its peak, the …

To the Editor—To and colleagues reported the first documented case of an asymptomatic
reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after 4.5 …

Background Group A rotaviruses are the most common cause of severe diarrhea in infants
and children worldwide and continue to have a major global impact on childhood morbidity …